PharmGKB: very important pharmacogene--HMGCR.
作者信息
Medina Marisa Wong, Sangkuhl Katrin, Klein Teri E, Altman Russ B
机构信息
Children's Hospital Oakland Research Institute, Oakland, California, USA.
出版信息
Pharmacogenet Genomics. 2011 Feb;21(2):98-101. doi: 10.1097/FPC.0b013e328336c81b.
Abstract
摘要
相似文献
1
PharmGKB: very important pharmacogene--HMGCR.药物基因组学知识库（PharmGKB）：非常重要的药物基因——3-羟基-3-甲基戊二酰辅酶A还原酶（HMGCR）
Pharmacogenet Genomics. 2011 Feb;21(2):98-101. doi: 10.1097/FPC.0b013e328336c81b.
2
PharmGKB summary: very important pharmacogene information for CYP2B6.药物基因组知识库总结：CYP2B6的非常重要的药物基因信息。
Pharmacogenet Genomics. 2010 Aug;20(8):520-3. doi: 10.1097/fpc.0b013e32833947c2.
3
[Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy].[他汀类药物治疗反应的个体差异以及他汀类药物治疗期间与肌病相关的基因多态性]
G Ital Cardiol (Rome). 2011 Mar;12(3):182-5.
4
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.药物基因组知识库摘要：细胞色素P450 2C8的非常重要的药物基因信息。
Pharmacogenet Genomics. 2013 Dec;23(12):721-8. doi: 10.1097/FPC.0b013e3283653b27.
5
HMGCR inhibits the early stage of PCV2 infection, while PKC enhances the infection at the late stage.HMGCR 抑制 PCV2 感染的早期阶段，而 PKC 则增强感染的晚期阶段。
Virus Res. 2017 Feb 2;229:41-47. doi: 10.1016/j.virusres.2016.12.010. Epub 2016 Dec 23.
6
Liver-specific deletion of 3-hydroxy-3-methylglutaryl coenzyme A reductase causes hepatic steatosis and death.肝特异性敲除 3-羟基-3-甲基戊二酰辅酶 A 还原酶导致肝脂肪变性和死亡。
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1824-31. doi: 10.1161/ATVBAHA.111.240754. Epub 2012 Jun 14.
7
Transcriptional regulation of HMG-CoA synthase and HMG-CoA reductase genes by human ACBP.人ACBP对HMG-CoA合酶基因和HMG-CoA还原酶基因的转录调控
Cell Physiol Biochem. 2008;22(5-6):515-24. doi: 10.1159/000185525. Epub 2008 Dec 9.
8
PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor.药物基因组知识库摘要：关于表皮生长因子受体的非常重要的药物基因信息。
Pharmacogenet Genomics. 2013 Nov;23(11):636-42. doi: 10.1097/FPC.0b013e3283655091.
9
A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.一项GoDARTS研究表明，HMG-CoA还原酶基因中的一种少态性变异与糖尿病患者对他汀类药物治疗的降脂反应有关。
Pharmacogenet Genomics. 2008 Dec;18(12):1021-6. doi: 10.1097/FPC.0b013e3283106071.
10
PharmGKB summary: very important pharmacogene information for CYP1A2.药物基因组知识库总结：关于CYP1A2的非常重要的药物基因信息。
Pharmacogenet Genomics. 2012 Jan;22(1):73-7. doi: 10.1097/FPC.0b013e32834c6efd.
引用本文的文献
1
A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with Genetic Variation in Parkinson's Disease.HMG-CoA 还原酶抑制剂的可能作用及其与帕金森病遗传变异的关联。
Int J Mol Sci. 2021 Nov 11;22(22):12198. doi: 10.3390/ijms222212198.
2
Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.高脂血症的个体化医学：药物遗传学在他汀类药物治疗中的作用。
Ann Med. 2020 Dec;52(8):462-470. doi: 10.1080/07853890.2020.1800074. Epub 2020 Aug 24.
3
SignaLink 2 - a signaling pathway resource with multi-layered regulatory networks.信号通路链接2 - 一个具有多层调控网络的信号通路资源。
BMC Syst Biol. 2013 Jan 18;7:7. doi: 10.1186/1752-0509-7-7.
4
Pharmacogenomics and bioinformatics: PharmGKB.药物基因组学和生物信息学：PharmGKB。
Pharmacogenomics. 2010 Apr;11(4):501-5. doi: 10.2217/pgs.10.15.
本文引用的文献
1
Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort.在“治疗新靶点”（TNT）队列中对他汀类药物治疗反应进行的全基因组和候选基因综合分析。
Circ Cardiovasc Genet. 2009 Apr;2(2):173-81. doi: 10.1161/CIRCGENETICS.108.818062. Epub 2009 Feb 12.
2
A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians.促动脉粥样硬化单核苷酸多态性的组合与亚洲印度人患冠状动脉疾病和心肌梗死的风险增加相关。
DNA Cell Biol. 2009 Sep;28(9):451-60. doi: 10.1089/dna.2009.0887.
3
The HMG-CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis.HMG-CoA还原酶基因与脂质及脂蛋白水平：动脉粥样硬化的多民族研究
Lipids. 2009 Aug;44(8):733-43. doi: 10.1007/s11745-009-3314-6. Epub 2009 Jun 25.
4
Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.HMG-CoA 还原酶（HMGCR）基因的变异影响多囊卵巢综合征的成分表型。
Fertil Steril. 2010 Jun;94(1):255-60.e1-2. doi: 10.1016/j.fertnstert.2009.01.158. Epub 2009 Mar 26.
5
A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.一项GoDARTS研究表明，HMG-CoA还原酶基因中的一种少态性变异与糖尿病患者对他汀类药物治疗的降脂反应有关。
Pharmacogenet Genomics. 2008 Dec;18(12):1021-6. doi: 10.1097/FPC.0b013e3283106071.
6
Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.密克罗尼西亚人和白人中与低密度脂蛋白胆固醇水平相关的HMGCR常见单核苷酸多态性影响外显子13的可变剪接。
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2078-84. doi: 10.1161/ATVBAHA.108.172288. Epub 2008 Sep 18.
7
Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.3-羟基-3-甲基戊二酰辅酶A还原酶的可变剪接与血浆低密度脂蛋白胆固醇对辛伐他汀的反应相关。
Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
8
Polymorphisms associated with cholesterol and risk of cardiovascular events.与胆固醇及心血管事件风险相关的多态性
N Engl J Med. 2008 Mar 20;358(12):1240-9. doi: 10.1056/NEJMoa0706728.
9
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.3-羟基-3-甲基戊二酰辅酶A还原酶基因的变异与辛伐他汀治疗后低密度脂蛋白胆固醇反应的种族差异相关。
Circulation. 2008 Mar 25;117(12):1537-44. doi: 10.1161/CIRCULATIONAHA.107.708388. Epub 2008 Mar 10.
10
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.普伐他汀对高胆固醇老年人血管事件及再发卒中的预防研究（PROSPER）中低密度脂蛋白受体和HMG-CoA还原酶基因位点的遗传变异、血脂水平、他汀类药物反应及心血管疾病发病率
Atherosclerosis. 2008 Sep;200(1):109-14. doi: 10.1016/j.atherosclerosis.2007.12.004. Epub 2008 Feb 7.
Zotero 插件